Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes extensive molecular simulations of the target protein alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that considers conformational mobility in both free and complex states. Potential binding pockets are examined on the protein-protein interaction interface and in distant allosteric sites to cover all possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P29965

UPID:
CD40L_HUMAN

ALTERNATIVE NAMES:
T-cell antigen Gp39; TNF-related activation protein; Tumor necrosis factor ligand superfamily member 5

ALTERNATIVE UPACC:
P29965

BACKGROUND:
The CD40 ligand, encoded by the gene P29965, serves as a critical mediator in the immune system. It binds to CD40 on B cells, facilitating immunoglobulin class switching and playing a role in T-cell activation and cytokine production. Its interactions with integrins highlight its importance in cell signaling and immune response modulation.

THERAPEUTIC SIGNIFICANCE:
Linked to Immunodeficiency with hyper-IgM, type 1, the CD40 ligand's dysfunction underscores its therapeutic potential. Targeting the CD40-CD40LG signaling pathway offers promising avenues for treating this life-threatening immunodeficiency and enhancing our understanding of immune regulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.